A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days.

Benson, C

White, J

De Bono, JS

O'Donnell, A

Raynaud, F

Cruickshank, C

McGrath, H

Frenz, L

Rose, F

Walton, M

Workman, P

Kaye, S

Journal Article

Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)

Br J Cancer. 2007, Jan 15, 1 (96), pp. 29 - 37

Publications Repository